Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Odedra

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
British Journal of Cancer|February 21, 2012
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft modelsS V Holt, A Logié, R Odedra, et al.
Cancer Biomarkers : Section a of Disease Markers|May 2, 2009
Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarkerM Hägg Olofsson, J Cummings, W Fayad, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
British Journal of Cancer|February 21, 2012
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft modelsS V Holt, A Logié, R Odedra, et al.
Cancer Biomarkers : Section a of Disease Markers|May 2, 2009
Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarkerM Hägg Olofsson, J Cummings, W Fayad, et al.
Pageof 2